16Indexed trials
mesh condition
Multiple Sclerosis, Relapsing-Remitting
Intelligence
Multiple Sclerosis, Relapsing-Remitting intelligence: 16 indexed trials, 5 recruiting studies, 13 sponsors across 34 countries.
5Recruiting
13Sponsors
34Countries
Leading sponsors
Hoffmann-La Roche32 recruiting
Washington University School of Medicine21 recruiting
Genentech, Inc.10 recruiting
Hope Biosciences Research Foundation11 recruiting
National Center of Neurology and Psychiatry, Japan10 recruiting
Anders Svenningsson10 recruiting
Teva Neuroscience, Inc.10 recruiting
Universidad de Almeria10 recruiting
University Hospital Muenster10 recruiting
University Hospital, Basel, Switzerland11 recruiting
University of Calgary10 recruiting
Queen Mary University of London10 recruiting
Geographic activity
United States6trials
Canada4trials
France3trials
United Kingdom3trials
Poland3trials
Germany3trials
Switzerland3trials
Spain3trials
Argentina2trials
Greece2trials
Japan2trials
Brazil2trials
Leading interventions
Ocrelizumab3trials
Fingolimod2trials
Autologous HB-adMSCs1trials
Dimethyl fumarate1trials
Domperidone1trials
Fingolimod Placebo1trials
Dimethyl Fumarate1trials
Glatiramer Acetate 20 mg/0.5 mL1trials
Glatiramer acetate 20 mg/0.5 mL1trials
Methylprednisolone1trials
Natalizumab1trials
Antihistamine1trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.